drugset / Trial / NCT04052932

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

NCT04052932

Phase 3 Completed 594 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout

Timeline

Start
2019-07-16
Primary completion
2021-07-14
Completion
2021-07-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg Oral
Subject SHR4640 Small molecule Oral

Indications